| Literature DB >> 20380886 |
Abstract
Xanthines such as theophylline have been used in the treatment of lung diseases since the early 1900's, but have a major drawback of a very narrow therapeutic window and many drug/drug interactions. With the increasing availability of other classes of drugs, this has limited the use of xanthines. Doxofylline is a xanthine molecule that appears to be both bronchodilator and anti-inflammatory with an improved therapeutic window over conventional xanthines such as theophylline and the evidence supporting the effects of doxofylline in the treatment of lung diseases is discussed. Copyright (c) 2010. Published by Elsevier Ltd.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20380886 DOI： 10.1016/j.pupt.2010.04.002
Source DB: PubMed Journal: Pulm Pharmacol Ther ISSN： 1094-5539 Impact factor: 3.410